(isobutyl carbonic) 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanoic anhydride | 849745-54-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 英文名称: (isobutyl carbonic) 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanoic anhydride
• CAS: 849745-54-6
• 化学式: C₁₇H₂₂N₄O₇
• 分子量: 394.384
• InChiKey: UBGCMQUGIUMRKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.44
• 重原子数：
  28.0
• 可旋转键数：
  10.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  146.69
• 氢给体数：
  1.0
• 氢受体数：
  10.0

反应信息

• 作为反应物：
  描述：

  (isobutyl carbonic) 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanoic anhydride 、 [(1R,3S,7S,8E,11S,12S,13E,15S,17R,21R,23S)-11,21-dihydroxy-17-(hydroxymethyl)-13-(2-methoxy-2-oxoethylidene)-10,10-dimethyl-19-oxo-6,18,27,28,29-pentaoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] 3-aminobenzoate 以 二氯甲烷 为溶剂， 反应 2.0h， 以75%的产率得到[(1R,3S,7S,8E,11S,12S,13E,15S,17R,21R,23S)-11,21-dihydroxy-17-(hydroxymethyl)-13-(2-methoxy-2-oxoethylidene)-10,10-dimethyl-19-oxo-6,18,27,28,29-pentaoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] 3-[6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanoylamino]benzoate
  参考文献：
  名称：

  Identification of a Tunable Site in Bryostatin Analogs:  C20 Bryologs through Late Stage Diversification

  摘要：

  [GRAPHICS]The C20 region of our bryostatin analogs was identified as a nonpharmacophoric site that could be varied to tune analogs for function and physical properties without significantly affecting their binding affinity for PKC. The use of this site in a late-stage diversification strategy has enabled the facile synthesis of a variety of new C20 analogs, all of which retain nanomolar affinity for PKC, in agreement with our pharmacophore hypothesis.

  DOI：

  10.1021/ol0501931
• 作为产物：
  描述：

  Methyl 6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanoate 在 sodium hydroxide 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 5.0h， 生成 (isobutyl carbonic) 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanoic anhydride
  参考文献：
  名称：

  Identification of a Tunable Site in Bryostatin Analogs:  C20 Bryologs through Late Stage Diversification

  摘要：

  [GRAPHICS]The C20 region of our bryostatin analogs was identified as a nonpharmacophoric site that could be varied to tune analogs for function and physical properties without significantly affecting their binding affinity for PKC. The use of this site in a late-stage diversification strategy has enabled the facile synthesis of a variety of new C20 analogs, all of which retain nanomolar affinity for PKC, in agreement with our pharmacophore hypothesis.

  DOI：

  10.1021/ol0501931